Cangrelor for treatment during percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitors is crucial post-percutaneous coronary intervention (PCI).
• Current oral P2Y12 inhibitors have delayed onset and slow offset of action, impacting immediate patient management.
• There is a need for antiplatelet agents with rapid onset and offset for PCI patients.

Purpose of the Study:

• To evaluate the efficacy and safety of cangrelor, an intravenous P2Y12 inhibitor, in patients undergoing PCI.
• To compare cangrelor's effectiveness and bleeding profile against oral agents like clopidogrel.

Main Methods:

• Three large, double-blind, randomized trials (CHAMPION PLATFORM, PCI, PHOENIX) were conducted.
• Patients received cangrelor (bolus + infusion) or clopidogrel/placebo during or after PCI.
• Efficacy endpoints included prevention of major adverse cardiovascular events; safety endpoints included major bleeding.

Main Results:

• Cangrelor demonstrated rapid platelet inhibition within minutes of administration.
• Normal platelet function was restored 1-2 hours after cangrelor cessation.
• The CHAMPION PHOENIX trial showed cangrelor was superior to clopidogrel in preventing adverse events without increasing major bleeding.

Conclusions:

• Cangrelor offers a rapid and reversible P2Y12 receptor inhibition.
• Its intravenous administration and fast pharmacokinetic profile may benefit select PCI patients.
• Cangrelor presents a valuable alternative for antiplatelet therapy in the PCI setting.